Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 9/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 3/20 | 0.66 |
| ▸ | BTK | Q06187 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | JAK1 | P23458 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | HCK | P08631 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018945 | 0.90 | MAP3K7 (0.78) | SRCMAP3K7FGFR1PTK2MAP2K1 | |
| SCHEMBL18018793 | 0.87 | EGFR (0.76) | SRCMAP3K7PTK2JAK3BTK | |
| SCHEMBL22807431 | 0.84 | SRC (0.69) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL22807484 | 0.82 | SRC (0.70) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL22807435 | 0.82 | MAP3K7 (0.76) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL29549166 | 0.82 | MAP3K7 (0.76) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL22828520 | 0.81 | SRC (1.00) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL31684786 | 0.81 | SRC (1.00) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL22807490 | 0.81 | SRC (0.83) | SRCMAP3K7FGFR1MAP2K1MAPK1 | |
| SCHEMBL22807377 | 0.81 | SRC (0.82) | SRCMAP3K7FGFR1MAP2K1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | SRC 2948/4885MAP3K7 166/4885FGFR1 3675/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | SRC 2948/4885MAP3K7 166/4885FGFR1 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.